Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Filamon LTD
Centre Oscar Lambret
PMV Pharmaceuticals, Inc
AstraZeneca
Washington University School of Medicine
University of Michigan Rogel Cancer Center
Rutgers, The State University of New Jersey
Eli Lilly and Company
BeOne Medicines
Psyence Australia Pty Ltd
ViroMissile, Inc.
Barbara Ann Karmanos Cancer Institute
Dana-Farber Cancer Institute
Duke University
University of Florida
AstraZeneca
Tizona Therapeutics, Inc
University of Florida
Essen Biotech
Essen Biotech
Eli Lilly and Company
Angiex, Inc.
IDEAYA Biosciences
Memorial Sloan Kettering Cancer Center
Centre Paul Strauss
Roswell Park Cancer Institute
Unity Health Toronto
Mälardalen University
Daiichi Sankyo
Memorial Sloan Kettering Cancer Center
Case Comprehensive Cancer Center
Guerbet
Eli Lilly and Company
Dana-Farber Cancer Institute
University of Michigan Rogel Cancer Center
HealthPartners Institute
Doma Biopharmaceutical(Suzhou)Co., Ltd.
Second Life Therapeutics
University of Kansas Medical Center
Medical College of Wisconsin
Fred Hutchinson Cancer Center
Apollo Therapeutics Ltd
OHSU Knight Cancer Institute
Innate Pharma
Ohio State University Comprehensive Cancer Center
MOMA Therapeutics
Mayo Clinic
Complement Theory Inc.